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It was estimated that over 600,000 new cases of hepatocellu-
ar carcinoma (HCC) were diagnosed each year worldwide and it
as in the second rank of the cancer mortality in men. Over three
uarter of these caseswas resided in Asia-Paciﬁc region, and half of
he worldwide cases were discovered in China. Chronic hepatitis B
HBV) is the most common causes of HCC in this region. Diagnosis
f the HCC, nodular size over 1 cm, is now based on speciﬁc pattern
f HCC which showed arterial enhancement and rapid wash out in
enous phases using Multi-detector CT scan or MRI. Liver biopsy is
seful for the deﬁnite diagnosis in a case with equivocal imaging
esult. AFP remained a useful marker in both screening and diag-
osis of HCC. As its moderate in sensitivity and speciﬁcity, recent
ASLD guideline decided to omit this test for both HCC screening
nd diagnosis. Among several staging systems, BCLC is widely used
s survival predictors and guideline of treatments. For the early
tage HCC, curative surgical resection or radiofrequency ablation
re used depending on the tumour location and medical exper-
ise in each unit. Liver transplantation for HCC is indicated in the
arly stage tumour (Milan’s criteria) in decompensated cirrhotic
iver or in cases of signiﬁcant portal hypertension, or in some sit-
ations of surgical/interventional difﬁculties. For the intermediate
tage of disease, TACE is most frequent used as palliative technic.
n the advance stages, targeted therapy with sorafenib have been
roved to increase survival outcome, even though small but signiﬁ-
antly. Particular aspects of HBV in management of HCC is whether
hese patients required nucleos(t)ide analogs in their course of dis-
ases. Firstly, treatment of HBV in cirrhotic condition, as published
n the several guidelines, has been proved to delay the disease
rogression and to improve the liver function status, especially in
ecompensated stage. Secondly, several reports demonstrated that
ral antiviral drugs could prevent the ﬂare up hepatitis after the
urgical resection or TACE. Lastly, in case of liver transplantation,
nhibition of viral replication with oral antiviral drugs during the
re-and post transplant periods are inevitably required.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.057nfectious Diseases 16S (2012) e2–e157 e21
Type: Invited Presentation
Final Abstract Number: 13.004
Session: Update on Hepatitis B
Date: Thursday, June 14, 2012
Time: 15:45-17:45
Room: Lotus 5-7
HBV-HEVdual infection and themolecular pathogenesis of hep-
atitis E
R.K. Ratho
Postgraduate Institute of Medical Education and Research (PGIMER),
Chandigarh, Chandigarh, India
Following molecular characterization in 1990, the putative
agent of waterborne viral hepatitis outbreak of 1955-56 at New
Delhi, India was conﬁrmed as Hepatitis E virus (HEV). HEV is a
spherical, 30-34nm, single stranded, positive sense RNA virus of
7.2 kb length. The genome consists of 3 open reading frames (ORF1,
ORF2, ORF3) where ORF1 encodes for large non-structural protein
having several putative functional motifs. ORF2 encodes the cap-
sid protein and the 50KDa spherical virus like particles. As it is
immunogenic in nature ORF2 is an important vaccine candidate.
ORF3 promotes cell survival and down regulation of innate host
responses through reduced expression of acute phase proteins.
An estimated 2 billion people live in HEV endemic areas, major-
ity of which belong to developing nations. The disease spans from
asymptomatic infection to acute viral hepatitis (AVH) and acute
liver failure (ALF), with high mortality ranging up to 30% in preg-
nancy. Recently chronic manifestations have also been reported in
organ transplant patients. Nearly 30-45% of ALF patients in Indian
subcontinent are positive for hepatitis E viral markers. The patho-
genesis ofHEV is poorly understood. In countrieswith intermediate
and high endemicity of Hepatitis B virus (HBV), the possibility of
acute exacerbation of Hepatitis B virus chronic liver disease is high
whichmight be associatedwith superinfectionwith any other hep-
atotropic viruses. Overall carrier rate of HBV in India is 4.7% placing
it in the intermediate range of endemicity and a carrier pool of
more than 5million. India is endemic for both enteric ally transmit-
ted Hepatitis A and E viruses and HEV has come up as an important
cause of acute exacerbation in previously asymptomatic andunrec-
ognized HBV-related Chronic liver disease. Seroprevalence studies
of viral hepatitis patients from Asian region have documented dual
infection of HBV and HEV. Such patients found to have more severe
hepatic inﬂammatory activity, raised liver enzymes, bilirubin and
lower Prothrombin activation timewith advanced liver disease and
a poorer prognosis. Majority of HBV infected patients in endemic
countries are vulnerable to infection with HEV and thus form the
ideal candidates for a future HEV vaccine.
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